drug · antibody
YUSIMRY
Marketedupdated 5mo agoby $COGT Cogent Biosciences, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval182 co-mentions · 86 sources
- drugHUMIRA172 co-mentions · 86 sources
- drugadalimumab152 co-mentions · 86 sources
- drugAMJEVITA81 co-mentions · 81 sources
- drugABRILADA81 co-mentions · 81 sources
- company$ABBVAbbVie Inc.61 co-mentions · 61 sources
- drugCYLTEZO24 co-mentions · 12 sources
- drugIDACIO16 co-mentions · 8 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
targets
Tumor necrosis factor
all catalysts(5)
approval · 5
Dec 17, 2021
approval
$COGT31.02-1.80%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Feb 27, 2023
approval
$COGT31.02-1.80%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Mar 31, 2023
approval
$COGT31.02-1.80%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Sep 13, 2023
approval
$COGT31.02-1.80%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Nov 10, 2025
approval
$COGT31.02-1.80%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
News(9)
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 1d ago
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin diseaseMerck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…biospace · 2d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…biospace · 23d ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 2mo ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 3mo ago
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.biopharma_dive · 3mo ago
- Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.stat · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that